Nasdaq · CIK 0001422142
WHWK Whitehawk Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 24 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at Whitehawk Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Bryan Ball See remarks sell | $5,045 2,147 shares | -2% | - | |
| 30Weak | David James Lennon CHIEF EXECUTIVE OFFICER sell | $13k 5,690 shares | -15% | - | |
| 27Weak | Scott M. Giacobello CHIEF FINANCIAL OFFICER sell | $6,594 2,806 shares | -10% | - |
Transactions
The last 46 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | David James Lennon CHIEF EXECUTIVE OFFICER | AGrant or award Stock option (right to buy)derivative | +193,957 | $0.00 | $0 | 193,957 | 24 d ago |
| Sep 15, 2026 | Scott M. Giacobello CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (right to buy)derivative | +118,476 | $0.00 | $0 | 118,476 | 24 d ago |
| Sep 15, 2026 | Margaret Dugan Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +81,250 | $0.00 | $0 | 81,250 | 24 d ago |
| Sep 15, 2026 | David Dornan Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +85,887 | $0.00 | $0 | 85,887 | 24 d ago |
| Sep 15, 2026 | Bryan Ball See remarks | AGrant or award Stock Option (right to buy)derivative | +91,633 | $0.00 | $0 | 91,633 | 24 d ago |
| Sep 15, 2026 | David James Lennon CHIEF EXECUTIVE OFFICER | AGrant or award Restricted Stock Unitsderivative | +193,957 | $0.00 | $0 | 193,957 | 24 d ago |
| Sep 15, 2026 | Scott M. Giacobello CHIEF FINANCIAL OFFICER | AGrant or award Restricted Stock Unitsderivative | +118,476 | $0.00 | $0 | 118,476 | 24 d ago |
| Sep 15, 2026 | Margaret Dugan Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +81,250 | $0.00 | $0 | 81,250 | 24 d ago |
| Sep 15, 2026 | David Dornan Chief Scientific Officer | AGrant or award Restricted Stock Unitsderivative | +85,887 | $0.00 | $0 | 85,887 | 24 d ago |
| Sep 15, 2026 | Bryan Ball See remarks | AGrant or award Restricted Stock Unitsderivative | +91,633 | $0.00 | $0 | 91,633 | 24 d ago |
| Sep 15, 2026 | Bryan Ball See remarks | AGrant or award Stock Option (right to buy)derivative | +91,633 | $0.00 | $0 | 91,633 | 27 d ago |
| Sep 15, 2026 | David James Lennon CHIEF EXECUTIVE OFFICER | AGrant or award Stock option (right to buy)derivative | +193,957 | $0.00 | $0 | 193,957 | 27 d ago |
| Sep 15, 2026 | Scott M. Giacobello CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (right to buy)derivative | +118,476 | $0.00 | $0 | 118,476 | 27 d ago |
| Sep 15, 2026 | Margaret Dugan Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +81,250 | $0.00 | $0 | 81,250 | 27 d ago |
| Sep 15, 2026 | David Dornan Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +85,887 | $0.00 | $0 | 85,887 | 27 d ago |
| Sep 15, 2026 | David James Lennon CHIEF EXECUTIVE OFFICER | AGrant or award Restricted Stock Unitsderivative | +193,957 | $0.00 | $0 | 193,957 | 27 d ago |
| Sep 15, 2026 | Scott M. Giacobello CHIEF FINANCIAL OFFICER | AGrant or award Restricted Stock Unitsderivative | +118,476 | $0.00 | $0 | 118,476 | 27 d ago |
| Sep 15, 2026 | Margaret Dugan Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +81,250 | $0.00 | $0 | 81,250 | 27 d ago |
| Sep 15, 2026 | David Dornan Chief Scientific Officer | AGrant or award Restricted Stock Unitsderivative | +85,887 | $0.00 | $0 | 85,887 | 27 d ago |
| Sep 15, 2026 | Bryan Ball See remarks | AGrant or award Restricted Stock Unitsderivative | +91,633 | $0.00 | $0 | 91,633 | 27 d ago |
| Sep 9, 2026 | Vijay K Iyengar director | AGrant or award Stock Option (right to buy)derivative | +76,080 | $0.00 | $0 | 76,080 | 31 d ago |
| Jun 12, 2025 | Neil Desai director | AGrant or award Stock Option (right to buy)derivative | +40,006 | $0.00 | $0 | 40,006 | Jun 17, 2025 |
| Jun 12, 2025 | Mohammad Hirmand director | AGrant or award Stock Option (right to buy)derivative | +40,006 | $0.00 | $0 | 40,006 | Jun 16, 2025 |
| Jun 12, 2025 | Anupam Dalal director | AGrant or award Stock Option (right to buy)derivative | +40,006 | $0.00 | $0 | 40,006 | Jun 16, 2025 |
| Jun 12, 2025 | Behzad Aghazadeh director, owner, other | AGrant or award Stock Option (right to buy)derivative | +40,006 | $0.00 | $0 | 40,006 | Jun 16, 2025 |
| Jun 12, 2025 | Caley Castelein director | AGrant or award Stock Option (right to buy)derivative | +40,006 | $0.00 | $0 | 40,006 | Jun 16, 2025 |
| Apr 1, 2025 | Bryan Ball See remarks | AGrant or award Stock Option (right to buy)derivative | +366,532 | $0.00 | $0 | 366,532 | Apr 3, 2025 |
| Apr 1, 2025 | Scott M. Giacobello CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (right to buy)derivative | +473,902 | $0.00 | $0 | 473,902 | Apr 3, 2025 |
| Apr 1, 2025 | Bryan Ball See remarks | AGrant or award Restricted Stock Unitsderivative | +366,532 | $0.00 | $0 | 366,532 | Apr 3, 2025 |
| Apr 1, 2025 | Scott M. Giacobello CHIEF FINANCIAL OFFICER | AGrant or award Restricted Stock Unitsderivative | +473,902 | $0.00 | $0 | 473,902 | Apr 3, 2025 |
| Mar 4, 2025 | Anupam Dalal director | AGrant or award Common Stockindirect: See footnote | +1,561,000 | $2.40 | $3.7M | 3,410,402 | Mar 5, 2025 |
| Mar 1, 2025 | Bryan Ball See remarks | MOption exercise Common Stock | +5,000 | - | - | 105,000 | Mar 4, 2025 |
| Feb 28, 2025 | Behzad Aghazadeh director, owner, other | AGrant or award Pre-funded Warrant (right to buy)derivativeindirect: See footnotes | +8,333,000 | $2.40 | $20M | 8,333,000 | Mar 4, 2025 |
| Mar 4, 2025 | Caley Castelein director | AGrant or award Common Stockindirect: See footnote | +1,666,000 | $2.40 | $4.0M | 2,165,998 | Mar 4, 2025 |
| Mar 4, 2025 | Baiteng Zhao director | AGrant or award Common Stockindirect: See footnote | +1,250,000 | $2.40 | $3.0M | 1,250,000 | Mar 4, 2025 |
| Mar 4, 2025 | David Dornan Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +687,979 | $0.00 | $0 | 687,979 | Mar 4, 2025 |
| Mar 3, 2025 | Bryan Ball See remarks | SOpen-market sale Common Stock | -2,147 | $2.35 | $5,045 | 102,853 | Mar 4, 2025 |
| Mar 4, 2025 | Bryan Ball See remarks | AGrant or award Common Stock | +100,000 | $2.40 | $240k | 202,853 | Mar 4, 2025 |
| Mar 1, 2025 | Bryan Ball See remarks | MOption exercise Restricted Stock Unitsderivative | -5,000 | $0.00 | $0 | 15,000 | Mar 4, 2025 |
| Mar 1, 2025 | David James Lennon CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +16,250 | - | - | 39,119 | Mar 3, 2025 |
| Mar 1, 2025 | Scott M. Giacobello CHIEF FINANCIAL OFFICER | MOption exercise Common Stock | +6,750 | - | - | 26,750 | Mar 3, 2025 |
| Mar 3, 2025 | David James Lennon CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -5,690 | $2.35 | $13k | 33,429 | Mar 3, 2025 |
| Mar 3, 2025 | Scott M. Giacobello CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock | -2,806 | $2.35 | $6,594 | 23,944 | Mar 3, 2025 |
| Mar 1, 2025 | Scott M. Giacobello CHIEF FINANCIAL OFFICER | MOption exercise Restricted Stock Unitsderivative | -6,750 | $0.00 | $0 | 20,250 | Mar 3, 2025 |
| Mar 1, 2025 | David James Lennon CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitsderivative | -16,250 | $0.00 | $0 | 48,750 | Mar 3, 2025 |
| Dec 19, 2024 | Baiteng Zhao director | AGrant or award Stock Option (right to buy)derivative | +61,192 | $0.00 | $0 | 61,192 | Dec 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Behzad Aghazadehdirector, owner, other
- Bryan BallSee remarks
- Caley Casteleindirector
- Anupam Dalaldirector
- Neil Desaidirector
- David DornanChief Scientific Officer
- Margaret DuganChief Medical Officer
- Scott M. GiacobelloCHIEF FINANCIAL OFFICER
- Mohammad Hirmanddirector
- Vijay K Iyengarofficer, director
- David James LennonCHIEF EXECUTIVE OFFICER
- Baiteng Zhaodirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.